- Company
- Samsung Biologics spins off Samsung Epis Holdings
- by Cha, Jihyun Nov 6, 2025 06:34am
- Samsung Biologics spun off its investment and subsidiary management business unit to establish Samsung Epis Holdings as a dedicated bio investment holding company The company announced on the 3rd that the holding company was officially established following a board resolution. Samsung Bioepis Holdings will establish separate subsidiaries
- Company
- GSK reattempts reimb for myelofibrosis drug Omjjara
- by Eo, Yun-Ho Nov 6, 2025 06:33am
- GSK’s myelofibrosis drug Omjjara (momelotinib), which failed reimbursement on its first attempt, is once again seeking insurance reimbursement in Korea. According to industry sources, GSK Korea recently resubmitted its reimbursement application for Omjjara. Despite its recent failure to be presented to the Health Insurance Review and Ass
- Company
- "Fosamax's value in osteoporosis sequential therapy rises"
- by Hwang, byoung woo Nov 6, 2025 06:32am
- As South Korea enters a super-aged society, the importance of long-term management in osteoporosis treatment is being emphasized. During this process, the bisphosphonate class of drugs, demonstrating long-term evidence and sustained efficacy, is once again becoming the key treatment strategy. DailyPharm met with Professor Beom-jun Kim of t
- Policy
- MFDS to ease orphan drug designation eligibility criteria
- by Lee, Tak-Sun Nov 6, 2025 06:32am
- As the criteria for Orphan Drug Designation are set to be significantly eased, this is expected to expand the introduction of rare disease treatments currently not approved in Korea. The Ministry of Food and Drug Safety (MFDS) plans to revise the regulations by February of next year. The MFDS announced this during the 'Top 50 Food and
- InterView
- ADCs rise to become SOC in key solid tumors
- by Son, Hyung Min Nov 6, 2025 06:32am
- Major antibody-drug conjugates (ADCs) are rapidly becoming standard-of-care (SOC) therapies across solid tumors, reshaping treatment paradigms. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has displaced Kadcyla (trastuzumab emtansine) as the new SOC in HER2-positive breast cancer. Enhertu is also validating potenti
- Company
- "Bavencio MT after short chemotherapy proves survival·QoL"
- by Hwang, byoung woo Nov 6, 2025 06:30am
- The treatment for urothelial carcinoma is shifting toward the direction of 'short chemotherapy, long survival'. The DISCUS study confirmed that there is no difference in treatment outcome even when platinum-based chemotherapy is administered for only three cycles. This evidence demonstrated that it can reduce unnecessary toxicity while maint
- Policy
- 'Zongertinib' for HER2-mutant NSCLC receives ODD
- by Lee, Tak-Sun Nov 5, 2025 06:25am
- Boehringer Ingelheim's 'zongertinib,' the first oral targeted therapy for patients with HER2-mutant non-small cell lung cancer (NSCLC) and which is gaining attention, received Orphan Drug Designation (ODD) from the Ministry of Food and Drug Safety (MFDS). The designation of the drug as an orphan drug is expected to accelerate its official
- Company
- 'Leqembi will reshape early dementia care landscape'
- by Hwang, byoung woo Nov 5, 2025 06:23am
- Leqembi (lecanemab), a therapy that directly removes the pathogenic protein driving Alzheimer's disease and slows disease progression, is opening a new treatment paradigm in a super-aged society. Unlike existing drugs that primarily focused on symptomatic relief, Leqembi has demonstrated disease-modifying potential, signaling broad changes ac
- Company
- Alfresa launches Jenecell to expand stem-cell business in KR
- by Chon, Seung-Hyun Nov 5, 2025 06:22am
- Alfresa Group, a major Japanese pharmaceutical distribution company, has entered the Korean market with the establishment of its subsidiary Jenecell and declared its entry into the stem cell business market. Alfresa Corporation announced on the 3rd that it has established Jenecell in Korea. The Alfresa Group is a Japanese healthcare compa
- Company
- Vyloy gains reimb momentum...targets gastric cancer mkt
- by Moon, sung-ho Nov 5, 2025 06:22am
- After clearing reimbursement review on its second attempt, Astellas’ Vyloy (zolbetuximab) is expected to reshape the metastatic gastric cancer treatment landscape. The entry of a targeted therapy option into a market previously dominated by immuno-oncology drugs presents a dilemma for treatment selection in clinical practice. Accordin
